Toray TRY-003D – Analysis by EarlyGuard™ miRNA from Women Referred for Additional Testing Due to Abnormal Breast Imaging Classified as Bl-RADS® of 3, 4, or 5 (Toray TRY-003D)
This protocol describes a simple, non-significant risk (NSR) clinical study, in which a single 5.0 – 10.0 mL sample of whole blood is drawn from each enrolled Subject meeting requirements of one of the three Study arms.
Suzanne Rose, PhD
Sponsor(s)Toray International America, Inc.
ContactHospitalist at 203-358-8879 or [email protected]
Bennett Cancer Center
Stamford, CT 06902